UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 593

Sortiert nach

Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae

Antimicrobial agents and chemotherapy, 2017-09, Vol.61 (9)

2017

Volltextzugriff (PDF)

Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015

Antimicrobial agents and chemotherapy, 2017-07, Vol.61 (7)

2017

Volltextzugriff (PDF)

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)

Antimicrobial Agents and Chemotherapy, 2013-12, Vol.57 (12), p.6305-6310

2013

Volltextzugriff (PDF)

Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States

Antimicrobial agents and chemotherapy, 2017-03, Vol.61 (3)

2017

Volltextzugriff (PDF)

Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae

Antimicrobial agents and chemotherapy, 2016-09, Vol.60 (9), p.5454-5458

2016

Volltextzugriff (PDF)

Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016

Diagnostic microbiology and infectious disease, 2018-09, Vol.92 (1), p.69-74

2018

Volltextzugriff (PDF)

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011)

Diagnostic microbiology and infectious disease, 2014-04, Vol.78 (4), p.443-448

2014

Volltextzugriff (PDF)

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17)

Journal of antimicrobial chemotherapy, 2018-11, Vol.73 (11), p.3053-3059

2018

Volltextzugriff (PDF)

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program

Antimicrobial agents and chemotherapy, 2018-04, Vol.62 (4)

2018

Volltextzugriff (PDF)

WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Volltextzugriff (PDF)

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018

Antimicrobial agents and chemotherapy, 2020-04, Vol.64 (5)

2020

Volltextzugriff (PDF)

Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015

Antimicrobial agents and chemotherapy, 2017-04, Vol.61 (4)

2017

Volltextzugriff (PDF)

Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections

Clinical infectious diseases, 2019-04, Vol.68 (Supplement_3), p.S200-S205

2019

Volltextzugriff (PDF)

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Volltextzugriff (PDF)

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016

Antimicrobial agents and chemotherapy, 2017-11, Vol.61 (11)

2017

Volltextzugriff (PDF)

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012

International journal of antimicrobial agents, 2014-04, Vol.43 (4), p.328-334

2014

Volltextzugriff (PDF)

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program

Antimicrobial agents and chemotherapy, 2018-12, Vol.62 (12)

2018

Volltextzugriff (PDF)

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

International journal of antimicrobial agents, 2018-08, Vol.52 (2), p.144-150

2018

Volltextzugriff (PDF)

Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016)

Journal of antimicrobial chemotherapy, 2019-06, Vol.74 (6), p.1595-1606

2019

Volltextzugriff (PDF)

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)

Journal of antimicrobial chemotherapy, 2014-10, Vol.69 (10), p.2713-2722

2014

Volltextzugriff (PDF)

Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China

Antimicrobial agents and chemotherapy, 2018-07, Vol.62 (7)

2018

Volltextzugriff (PDF)

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates

Antimicrobial agents and chemotherapy, 2018-01, Vol.62 (1)

2018

Volltextzugriff (PDF)

In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018

Antimicrobial agents and chemotherapy, 2019-11, Vol.63 (11)

2019

Volltextzugriff (PDF)

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018)

Diagnostic microbiology and infectious disease, 2020-03, Vol.96 (3), p.114833-114833, Article 114833

2020

Volltextzugriff (PDF)

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program

Diagnostic microbiology and infectious disease, 2018-10, Vol.92 (2), p.158-163

2018

Volltextzugriff (PDF)

1 – 25 von 593

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(562)
Mit Volltextzugriff
(553)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(382)
Life Sciences & Biomedicine
(377)
Humans
(251)
Microbiology
(228)
Infectious Diseases
(183)
Anti-Bacterial Agents - Pharmacology
(177)
Pharmacology & Pharmacy
(175)
Microbial Sensitivity Tests
(172)
Biological And Medical Sciences
(126)
Medical Sciences
(115)
Male
(71)
Female
(70)
United States
(69)
Anti-Bacterial Agents
(66)
Pharmacology. Drug Treatments
(65)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(61)
Middle Aged
(61)
Adult
(56)
Cephalosporins - Pharmacology
(56)
Staphylococcus Aureus
(56)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae

Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)

Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States

Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae

Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011)

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17)

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program

WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018

Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015

Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016)

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)

Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates

In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018)

Suchergebnisse filtern